DBV TECHNOLOGIES S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.682 USD | -1.08% |
|
+0.04% | -28.42% |
| Sales 2024 * | 6.53M 6.99M 560M | Sales 2025 * | 4.89M 5.22M 418M | Capitalization | 114M 122M 9.77B |
|---|---|---|---|---|---|
| Net income 2024 * | -107M -114M -9.16B | Net income 2025 * | -74M -79.12M -6.34B | EV / Sales 2024 * | -8.63 x |
| Net cash position 2024 * | 170M 182M 14.6B | Net cash position 2025 * | 224M 239M 19.17B | EV / Sales 2025 * | -22.4 x |
| P/E ratio 2024 * |
-1.54
x | P/E ratio 2025 * |
-2.76
x | Employees | 105 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.11% |
More Fundamentals
* Assessed data
More news
Latest transcript on DBV Technologies S.A.
More press releases
More news
| 1 day | -1.08% | ||
| 1 week | +0.04% | ||
| Current month | -8.96% | ||
| 1 month | -11.05% | ||
| 3 months | -23.80% | ||
| 6 months | -36.26% | ||
| Current year | -28.42% |
1 week
0.65
0.72
1 month
0.650.83
Current year
0.650.99
1 year
0.652.37
3 years
0.656.88
5 years
0.6513.49
10 years
0.6550.57
| Managers | Title | Age | Since |
|---|---|---|---|
Daniel Tassé
CEO | Chief Executive Officer | 64 | 28/11/18 |
| Director of Finance/CFO | 54 | 11-05 | |
Pharis Mohideen
CTO | Chief Tech/Sci/R&D Officer | 59 | 21/07/19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Timothy Morris
BRD | Director/Board Member | 61 | 28/02/21 |
Michel de Rosen
CHM | Chairman | 73 | 21/06/18 |
Don Soland
BRD | Director/Board Member | 65 | 05/03/15 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.03% | 0 M€ | 0.00% | - | |
| 0.02% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 0.682 | -1.08% | 41,558 |
| 25/04/24 | 0.6894 | -0.22% | 40,904 |
| 24/04/24 | 0.691 | +1.62% | 2,576 |
| 23/04/24 | 0.68 | +2.87% | 116,976 |
| 22/04/24 | 0.661 | -3.04% | 43,412 |
Delayed Quote Nasdaq, April 26, 2024 at 09:30 pm
More quotes
DBV Technologies specializes in developing solutions for diagnosing and treating food allergies (primarily to peanuts and cow's milk) using a patch (Viaskin®) that administers active ingredients into the top layers of the skin.
Sector
Pharmaceuticals
Calendar
01/05/2024
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
1.186
EUR
Average target price
4.783
EUR
Spread / Average Target
+303.32%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +5.31% | 70.44B | |
| +10.97% | 8.94B | |
| -16.83% | 4.75B | |
| +43.48% | 4.5B | |
| +3.20% | 3.85B | |
| -21.36% | 2.34B | |
| -29.67% | 2.2B | |
| +8.38% | 1.96B | |
| +3.90% | 1.65B |
- Stock Market
- Equities
- DBV Stock
- DBVT Stock
